INTRODUCTION
In the treatment of Parkinson's disease (PD) neural transplantation is among the most innovative and controversial approaches. By successfully implanting functionally active dopaminergic cells into the striatum, the fundamental problem of PD-namely, the deficient dopaminergic nigrostriatal pathway-could be theoretically corrected. Open label studies just document improvements, although no cases of symptom resolution exist, and no patient has been cured. Furthermore clinical experience shows that PD is not exclusively a motor disease, and pathological research documents dopamine loss outside the nigrostriatal circuit. As cognitive impairment can be an irrefutable companion of motor incapacity and pharmacological treatment can cause serious neurobehavioral problems, it is pivotal to determine the specific impact of transplants on intellectual and emotional function. At least three mechanisms must be considered: (1) dopamine secreted by the transplanted cells and interacting with the new environment; (2) the lesion due to the
